Etablierte und experimentelle Prognosefaktoren des Ovarialkarzinoms

 

 Buy Article Permissions and Reprints

Zusammenfassung

Das Ovarialkarzinom ist das vierthäufigste Malignom der europäischen Frau, nimmt aber mit seiner schlechten Prognose den 1. Platz in der Mortalitätsstatistik der gynäkologischen Malignome ein.Eine Vielzahl von Prognosefaktoren sind beim Ovarialkarzinom bisher identifiziert worden, die jedoch aufgrund ungenügender Daten bezüglich ihres Stellenwertes als „echter” Prognosefaktor in der Literatur häufig kontrovers diskutiert werden. Mit dem kontinuierlich wachsenden Verständnis der Tumorbiologie des Ovarialkarzinoms und mit Hilfe neuer molekularbiologischer Techniken lassen sich zunehmend weitere potenzielle Prognosefaktoren identifizieren, die jedoch meist noch auf die Bestätigung durch größere Fallserien warten lassen.Der vorliegende Beitrag diskutiert den Stellenwert konventioneller Prognosefaktoren, wie Tumorstadium, Alter, postoperativer Tumorrest, Lymphknotenstatus, Aszites und neueren propagierten Faktoren, wie Her-2-Status, PAI-1, MMP, VEGF und CD24.

Abstract

Epithelial ovarian cancer is the leading cause of death from gynaecologic malignancies in western countries. In the clinical day treatment decision of the physician (e. g. surgery, chemotherapy) based on individual prognostic factors of the patient with ovarian cancer.The tumor stage at time of diagnosis and the postoperative residual tumor mass are prognostic factors and are unequivocally related to overall survival. Other prognostic factors are identified mostly in small series and are discussed in the literature controversially.This article discussing the value of conventional prognostic factors, as stage, postoperative tumor mass, age, lymph node status, ascites) and newer molecular biological factors, as Her-2-status, PAI-1, MMP, VEGF and CD24.

Literatur

• 1 Ali-Fehmi R, Che M, Khalifeh I, Malone J M, Morris R, Lawrence W D, Munkarah A R. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.  Cancer. 2003;  98 1423-1429
  CrossrefPubMedGoogle Scholar
• 2 Avarez L D, To A, Boots L R. et al . CA 125 as a serum marker for poor prognosis in ovarian malignancies.  Gynecol Oncol. 1987;  26 284-289
  CrossrefPubMedGoogle Scholar
• 3 Baiocchi G, Grosso G, Di Re E. Systematic pelvic and peraortic lymphadenectomy at second look laparotomy for ovarian cancer.  Gynecol Oncol. 1998;  69 151-156
  CrossrefPubMedGoogle Scholar
• 4 Bridgewater J A, Nelstrop A E, Rustin G J, Gore M E, McGuire W P, Hoskins W J. Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel.  J Clin Oncol. 1999;  17 501-508
  PubMedGoogle Scholar
• 5 Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.  J Clin Oncol. 2002;  20 1248-1259
  CrossrefPubMedGoogle Scholar
• 6 Burger R A, Grosen E A, Ioli G R, Van Eden M E, Brightbill H D, Gatanaga M, DiSaia P J, Granger G A, Gatanaga T. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.  Gynecol Oncol. 1994;  55 294-303
  CrossrefPubMedGoogle Scholar
• 7 Burghardt E, Girardi F, Lahousen M. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer.  Gynecol Oncol. 1991;  40 103-106
  CrossrefPubMedGoogle Scholar
• 8 Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer.  Am J Obstet Gynecol. 1986;  155 315-319
  PubMedGoogle Scholar
• 9 Carnino F, Fuda G C, Ciccone G, Iskra L, Guercio E, Dadone D, Conte P F. Significance of Lymph Node Sampling in Epithelial Carcinoma of the Ovary.  Gynecol Oncol. 1997;  65 467-472
  CrossrefPubMedGoogle Scholar
• 10 Chambers S, Ivins M, Carcangiu M. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.  Int J Cancer (Pred Oncol). 1998;  79 449-454
  CrossrefPubMedGoogle Scholar
• 11 Chi D S, Liao J B, Leon L F, Venkatraman E S, Hensley M L, Bhaskaran D, Hoskins W J. Identification of prognostic factors in advanced epithelial ovarian carcinoma.  Gynecol Oncol. 2001;  82 532-537
  CrossrefPubMedGoogle Scholar
• 12 Cobleigh M A, Vogel C L, Tripathy D, Robert N J, Scholl S, Fehrenbacher L, Wolter J M, Paton V, Shak S, Lieberman G, Slamon D J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breastcancer that has progressed after chemotherapy for metastatic disease.  J Clin Oncol. 1999;  17 2639-2648
  CrossrefPubMedGoogle Scholar
• 13 Cooper B C, Sood A K, Davis C S, Ritchie J M, Sorosky J I, Anderson B, Buller R E. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.  Obstet Gynecol. 2002;  100 59-64
  CrossrefPubMedGoogle Scholar
• 14 Dembo A J, Davy M, Stenwig A E, Berle E J, Bush R S, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer.  Obstet Gynecol. 1990;  75 263-273
  PubMedGoogle Scholar
• 15 Denkert C, Kobel M, Pest S. et al . Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.  Am J Pathol. 2002;  160 893-903
  PubMedGoogle Scholar
• 16 Di Re F, Baiocchi G, Fontanelli R, Gross G. et al . Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastasis.  Gynecol Oncol. 1996;  62 360-365
  CrossrefPubMedGoogle Scholar
• 17 Dt. Krebsgesellschaft .Kurzgefasste Interdisziplinäre Leitlinien. Maligne Ovarialtumoren. 3. Aufl. W. Zuckschwerdt-Verlag, München, Bern, Wien, New York 2002
  Google Scholar
• 18 du Bois A, Luck H J, Meier W, Adams H P, Mobus V, Costa S. et al . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
  CrossrefPubMedGoogle Scholar
• 19 Eisenkop S M, Friedman R L, Spirtos N M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.  Cancer. 2000;  88 144-153
  CrossrefPubMedGoogle Scholar
• 20 Eisenkop S M, Friedman R L, Wang H J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study.  Gynecol Oncol. 1998;  69 103-108
  CrossrefPubMedGoogle Scholar
• 21 Eisenkop S M, Friedman R L, Wang H J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study.  Gynecol Oncol. 1998;  69 103-108
  CrossrefPubMedGoogle Scholar
• 22 Elbendare A A, Berchuk A, Bast R C. Biology of epithelial ovarian cancer. In: Lawton FG, Neijt JP, Swenerton KD. Epithelial cancer of the ovary. BMJ Publishing Group, London 1995; 20-25
  Google Scholar
• 23 Enomoto T, Kuragaki C, Yamasaki M, Sugita N. et al .Is Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary Sensitive to Combination Chemotherapy with Paclitaxel and Carboplatin?. 39th ASCO Annual Meeting 2003; Abstract 1797
  Google Scholar
• 24 Fajac A, Benard J, Lhomme K. C-erB2gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis.  Int J Cancer (Pred Oncol). 1995;  65 146-151
  PubMedGoogle Scholar
• 25 Ferrandina G, Lauriola L, Zannoni G F, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti F O, Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.  Ann Oncol. 2002;  13 1205-1211
  CrossrefPubMedGoogle Scholar
• 26 Geisler J P, Miller G A, Lee T H, Harwood R M, Wiemann M C, Geisler H E. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.  J Reprod Med. 1996;  41 140-142
  PubMedGoogle Scholar
• 27 Geisler J P, Wiemann M C, Miller G A. et al . Estrogen and progesterone receptor status as prognostic indicator in patients with optimally cytoreduced stage IIIc serous cystadenocarcinomaof the ovary.  Gynecol Oncol. 1996;  60 424-427
  CrossrefPubMedGoogle Scholar
• 28 Gotlieb W H, Abrams J S, Watson J M, Velu T J, Berek J S, Martinez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers.  Cytokine. 1992;  4 385-390
  CrossrefPubMedGoogle Scholar
• 29 Hess V, A'Hern R P, Gore M E. Relative Platinum-Resistance of Mucinous Carcinoma of the Ovary. 39th ASCO Annual Meeting 2003; Abstract 1796
  Google Scholar
• 30 Hoskins W. Surgical staging and cytoreductive surgery of epithelial ovarian cancer.  Cancer. 1993;  71 1534-1540
  PubMedGoogle Scholar
• 31 Hoskins W J, McGuire W P, Brady M F, Homesley H D, Creasman W T, Berman M, Ball H, Berek J S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.  Am J Obstet Gynecol. 1994;  170 974-980
  PubMedGoogle Scholar
• 32 Hsieh C Y, Chen C A, Chou C H, Lai K P, Jeng Y M, Kuo M L, Wei L H. Overexpression of Her-2/NEU in Epithelial Ovarian Carcinoma Induces Vascular Endothelial Growth Factor C by Activating NF-kappaB: Implications for Malignant Ascites Formation and Tumor Lymphangiogenesis.  J Biomed Sci. 2004;  11 249-259
  CrossrefPubMedGoogle Scholar
• 33 Jacobs I J, Menon U. Progress challenges in screening for early detection of ovarian cancer.  Mol Cell Proteomics. 2004;  3 355-366
  PubMedGoogle Scholar
• 34 Jacobs J, Oram J, Fairbanks, Turner J, Frost C, Grudzinskas J G. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.  Br J Obstet Gynecol. 1990;  97 922-992
  PubMedGoogle Scholar
• 35 Kikkawa F, Kawai M, Mizuno, Ishikawa H, Kojima M, Maeda O, Tamakoshi K, Suganuma N, Tomoda Y, Hattori S. Recurrence of epithelial ovarian carcinoma after clinical remission.  Gynecol Obstet Invest. 1994;  38 65-69
  PubMedGoogle Scholar
• 36 Kindermann G, Maassen V, Kuhn W. Laparoscopic management of ovarian tumors subsequently diagnosed as malignant: a survey from 127 German departments of obstetrics and gynecology.  J Pelvic Surgery. 1996;  2 245-251
  PubMedGoogle Scholar
• 37 Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis E P. Human kallikrein 8, a novel biomarker for ovarian carcinoma.  Cancer Res. 2003;  63 2771-2774
  PubMedGoogle Scholar
• 38 Klemi P J, Joensuu H, Salmi T. Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of the ovary.  Cancer. 1990;  65 1189-1193
  PubMedGoogle Scholar
• 39 Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects.  Gynecol Oncol. 1992;  47 317-322
  CrossrefPubMedGoogle Scholar
• 40 Kristiansen G, Denkert C, Schluns K. et al . CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.  Am J Pathol. 2002;  161 1215-1221
  PubMedGoogle Scholar
• 41 Kuhn W, Schmalfeldt B, Reuning U. et al . Prognostic significance of urokinase (uPA) und ts inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO III c.  Br J Cancer. 1999;  79 1746-1751
  CrossrefPubMedGoogle Scholar
• 42 Kupryjanczyk J, Thor A D, Beauchamp R, Poremba C, Scully R E, Yandell D W. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.  Mod Pathol. 1996;  9 166-173
  PubMedGoogle Scholar
• 43 Landis S H, Murray T, Bolden S. Cancer Statistic.  CA Cancer J Clin. 1999;  8 49-54
  PubMedGoogle Scholar
• 44 Lavin P T, Knapp R C, Malkasian G. et al . CA-125 for the monitoring of ovarian carcinoma during primary therapy.  Obstet Gynecol Gynecol. 1987;  69 223-227
  PubMedGoogle Scholar
• 45 Lengyel E, Schmalfeldt B, Konik E. et al . Expression of latent matrix metalloproteinase-9 predicts survival in advanced ovarian cancer.  Gynecol Oncol. 2001;  82 291-298
  CrossrefPubMedGoogle Scholar
• 46 Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer.  J Obstet Gyn Res. 1998;  24 447-451
  PubMedGoogle Scholar
• 47 Lück H .J, Kommoss F, Riener E. et al . HER2-expression in advanced ovarian cancer: A prognostic and predictive marker?.  Eur J Cancer. 2003;  39 (Suppl 1) 16
  PubMedGoogle Scholar
• 48 Maggioni A, Maneshi F, Maggioni C. et al . Randomized trial of lymphadenektomie (LY) vs, sampling (SA) or resection of bulky nodes (RBN) as primary surgical procedure in early epithelial ovarian cancer.  Int J Gynecol Cancer. 1999;  9 43
  PubMedGoogle Scholar
• 49 Makar A, Baekelandt M, Tropè C O, Kristensen G B. The prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian Cancer.  Gynecol Oncol. 1995;  56 175-180
  CrossrefPubMedGoogle Scholar
• 50 Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.  Eur J Cancer. 2003;  39 1948-1956
  CrossrefPubMedGoogle Scholar
• 51 Mayr D, Diebold J. Grading of ovarian carcinomas.  Int J Gynecol Pathol. 2000;  19 348-353
  PubMedGoogle Scholar
• 52 Meerpohl H G. Prognostic factors of ovarian cancer.  Onkologie. 1985;  8 296-304
  PubMedGoogle Scholar
• 53 Meigs J V. Tumors of the female pelvic organs. Mc Millan, New York 1934
  Google Scholar
• 54 Munnel E W. The changing prognosis and treatment in cancer of the ovary.  Am J Obstet Gynecol. 1968;  100 790
  PubMedGoogle Scholar
• 55 Menon U, Talaat A, Rosenthal A N, Macdonald N D, Jeyerajah A R, Skates S J, Sibley K, Oram D H, Jacobs I J. Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening.  Br J Obstet Gynecol. 2000;  107 165-169
  PubMedGoogle Scholar
• 56 Mujoo K, Watanabe M, Nakamura J, Khokhar A R, Siddik Z H. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.  J Cancer Res Clin Oncol. 2003;  129 709-718
  CrossrefPubMedGoogle Scholar
• 57 NIH . National Institutes of Health Consensus Development Conference Statement. Ovarian Cancer: Screening, Treatment, and Follow-up.  Gynecol Oncol. 1994;  55 4-12
  CrossrefPubMedGoogle Scholar
• 58 Omura G A, Brady M F, Homesley H D, Yordan E, Major F J, Buchsbaum H J, Park R C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.  J Clin Oncol. 1991;  9 1138-1150
  PubMedGoogle Scholar
• 59 Paley P J, Staskus K A, Gebhard K. et al . Vascular endothelial growth factor expression in early stage ovarian carcinoma.  Cancer. 1997;  80 98-106
  CrossrefPubMedGoogle Scholar
• 60 Panici P B, Angioli R. Role of lymphadenectomy in ovarian cancer.  Best Practice & Res Clin Obstet Gynecol. 2002;  16 529-551
  PubMedGoogle Scholar
• 61 Parazzini F, Valsecchi G, Bolis G. et al . Pelvic and paraaortic Lymph nodal status in advanced ovarian cancer and survival.  Gynecol Oncol. 1999;  74 7-11
  CrossrefPubMedGoogle Scholar
• 62 Parker D, Bradley C, Bogle S M, Lay J, Masood M, Hancock A K, Naylor B, Price J J. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer.  Br J Obstet Gynecol. 1994;  101 888-893
  PubMedGoogle Scholar
• 63 Pecorelli S, Benedet J, Beller U, Creasman W, Heintz A, Pettersson F. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. Isis Medical Media Ltd., Oxford, England 2001; 6: 1-184
  Google Scholar
• 64 Pecorelli S, Boyle P, Odicino F, Sideri M Maisonneuve P, Severi G, Zigliani L. FIGO Annual Report on the Results on the Treatment in Gynaecological Cancer.  J Epidemiol Biostat. 1998;  3 1-168
  PubMedGoogle Scholar
• 65 Pfisterer J, Kommoss F, Sauerbrei W. et al . Cellular DNA content and survival in advanced ovarian carcinoma.  Cancer. 1994;  74 2509-2515
  PubMedGoogle Scholar
• 66 Pisa P, Halapi E, Pisa E K, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.  Proc Natl Acad Sci USA. 1992;  89 7708-7712
  PubMedGoogle Scholar
• 67 Puls L E, Duniho T, Hunter J E, Kryscio R, Blackhurst D, Gallion H. The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer.  Gynecol Oncol. 1996;  61 109-112
  CrossrefPubMedGoogle Scholar
• 68 Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. Zytokinspiegel im malignen Aszites und peripheren Blut von Patientinnen mit fortgeschrittenem Ovarialkarzinom.  Geburtsh Frauenheilkd. 1996;  56 83-87
  PubMedGoogle Scholar
• 69 Rahaman J, Jennings T S, Dottino P, Cohen C J. Impact of Age on Survival in Advanced Ovarian Cancer: a Re-Examination. Proceedings of ASCO unter www.asco.org. 2001; Abstract 866
  Google Scholar
• 70 Reles A, Press M F, Schönborn I, Lichtenegger W, Strohmeyer T. p53 Proteinuberexpression in Ovarialkarzinomen: Korrelation mit histopathologischen Daten und klinischem Verlauf.  Gynäkol Geburtsh Rundsch. 1995;  35 (Suppl 1) 93-97
  PubMedGoogle Scholar
• 71 Reles A, Wen W H, Schmider A, Gee C, Runnebaum I B, Kilian U, Jones L A, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press M F. p53 mutations and expression in ovarian cancers: correlation with overall survival.  Int J Gynecol Pathol. 1999;  18 29-41
  PubMedGoogle Scholar
• 72 Roszkowski P, Wronkowski Z, Szamborski J. et al . Evaluation of selected prognostic factors in ovarian cancer.  Eur J Gynecol Oncol. 1993;  14 (Suppl) 140-145
  PubMedGoogle Scholar
• 73 Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K. Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma. 38th ASCO Annual Meeting 2002; Abstract 801
  Google Scholar
• 74 Scambia G, Testa U, Benedetti-Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer.  Br J Cancer. 1995;  71 354-356
  PubMedGoogle Scholar
• 75 Scambia G, Testa U, Panici P B, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S. Interleukin-6 serum levels in patients with gynecological tumors.  Int J Cancer. 1994;  57 318-323
  PubMedGoogle Scholar
• 76 Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase- type plasminogen activator is associated with progression from benign to advanced ovarian cancer.  Clin Cancer Res. 2001;  8 2396-2404
  PubMedGoogle Scholar
• 77 Schmider A, Gee C, Friedmann W, Lukas J J, Press M F, Lichtenegger W, Reles A. P21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma.  Gynecol Oncol. 2000;  77 237-242
  CrossrefPubMedGoogle Scholar
• 78 Schneider D, Halperin R, Halperin D, Bukovsky I, Hadas E. Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system.  Eur J Gynecol Oncol. 1998;  19 547-552
  PubMedGoogle Scholar
• 79 Scully R E, Silva E. Pathology of ovarian cancer. In: Gersheson GM, McGuire WP (eds). Ovarian Cancer. Controversies in management. Churchill Livingstone, New York, Edinburgh, London, Madrid, Melbourne, San Francisco, Tokio 1988; 425-444
  Google Scholar
• 80 Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtengger W. Preoperative Determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the Discrimination between Benign and Malignant Pelvic Tumor Mass: A Prospective Study.  Anticancer Res. 2003;  23 1115-1118
  PubMedGoogle Scholar
• 81 Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W. “IMO” - Intraoperative Mapping of Ovarian Cancer.  Zentralbl Gynakol. 2003;  125 129-135
  Article in Thieme ConnectPubMedGoogle Scholar
• 82 Sevelda P, Vavra N, Schemper M. et al . Prognostic factors for survival in stage I epithelial ovarian carcinoma.  Cancer. 1990;  65 2349-2352
  PubMedGoogle Scholar
• 83 Silverberg S G. Prognostic significance of pathologic features of ovarian carcinoma (Review).  Current Topics Pathol. 1989;  78 85-109
  PubMedGoogle Scholar
• 84 Sliutz G. Prognosefaktoren beim Ovarialkarzinom.  Wien, Med Wochenschr. 1996;  146 14-17
  PubMedGoogle Scholar
• 85 Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor.  Int J Gynecol Cancer. 2004;  14 82-88
  CrossrefPubMedGoogle Scholar
• 86 Sowter H M, Corps A N, Evans A L, Clark D E, Charnock-Jones D S, Smith S K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.  Lab Invest. 1997;  77 607-614
  PubMedGoogle Scholar
• 87 Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients.  Gynecol Oncol. 1997;  66 27-30
  CrossrefPubMedGoogle Scholar
• 88 Thigpen T, Brady M F, Omura G A, Creasman W T, McGuire W P, Hoskins W J, Williams S. Age as prognostic factor in ovarian carcinoma.  Cancer. 1993;  71 606-614
  PubMedGoogle Scholar
• 89 Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K. et al . Relationship between Paraaortic Lymph Node Involvement and Intraperitoneal Spread in Patients with Ovarian Cancer-a multivariate Analysis.  Gynecol Oncol. 1993;  49 51-55
  CrossrefPubMedGoogle Scholar
• 90 van der Burg M EL, Lammes F B, Verweij J. et al . The role of CA125 in the early diagnosis of progresive disease in ovarian cancer.  Ann Oncol. 1990;  1 301-302
  PubMedGoogle Scholar
• 91 Vergote I B, Bormer O P, Abeler V M. Evaluation of serum CA125 levels in the monitoring of ovarian cancer.  Am J Obstet Gynecol. 1987;  157 88-92
  PubMedGoogle Scholar
• 92 Vergote I B, De Brabanter J, Fyles A. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.  Lancet. 2001;  357 176-182
  CrossrefPubMedGoogle Scholar
• 93 Vergote I B, Kaern J, Abeler V. et al . Analysis of prognostic factors in stage I epithelial ovarian cancer: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.  Am J Obstet Gynecol. 1993;  169 40-52
  PubMedGoogle Scholar
• 94 Walter A J, Magrina J F. Contralateral pelvic and aortic lymph node metastasis in clinical stage I epithelial ovarian cancer.  Gynecol Oncol. 1999;  74 128-129
  CrossrefPubMedGoogle Scholar
• 95 Watson J M, Sensintaffar J L, Berek J S, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.  Cancer Res. 1990;  50 6959-6965
  PubMedGoogle Scholar
• 96 Wong C, Wellman T L, Lounsbury K M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.  Gynecol Oncol. 2003;  91 513-517
  CrossrefPubMedGoogle Scholar
• 97 Wu P C, Qu J Y, Lang J H. Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy.  Am J Obstet Gynecol. 1986;  155 1103-1108
  PubMedGoogle Scholar
• 98 Yokoyama Y, Charnock-Jones D S, Licence D. et al . Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma.  Br J Cancer. 2003;  88 237-244
  CrossrefPubMedGoogle Scholar
• 99 Zeimet A G. et al . Ascitic Interleucin-12 is an independent prognostic factor in ovarian cancer.  J Clin Oncol. 1998;  16 1861-1866
  PubMedGoogle Scholar

Dr. Jalid Sehouli

Universitätsklinikum Charité · Klinik für Frauenheilkunde und Geburtshilfe · Campus Virchow-Klinikum

Augustenburger Platz 1

13353 Berlin

Phone: 0 30/4 50 56 40 52

Fax: 0 30/4 50 56 49 52

Email: Sehouli@aol.com